Device manufacturer, as written on reports
Medtronic Cardiovascular Galway: medical device reports filed with FDA
3,837 reports name it as the manufacturer of the device involved, 2008–2015.
- 3,837
- reports naming it as manufacturer
- 0% of all MAUDE reports
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 22.7%
- classified as malfunction
- 62.3% across all reports
- 15.4%
- classified as death, as reported
- 0.9% across all reports
3,837 medical device reports received by FDA give Medtronic Cardiovascular Galway as the manufacturer of the device involved, 0% of the MAUDE database, from February 2008 to February 2015. Manufacturer names are as written on the report; subsidiaries and spelling variants may appear as separate names.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (61.8%), malfunction (22.7%) and death (15.4%). Manufacturers are required to report events they learn of, so a large manufacturer with many products in use files many reports. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Brands named most often
| Brand | Device type | Reports | Latest 12 months | Classified as death |
|---|---|---|---|---|
| Endeavor Sprint Rx Coronary Stent System | Coronary drug-eluting stent | 1,029 | 0 | 17.4% |
| Endeavor Rx Coronary Stent System | Coronary drug-eluting stent | 437 | 0 | 27% |
| Talent Abdominal Stent Graft System - Hydro | System, endovascular graft, aortic aneurysm treatment | 263 | 0 | 12% |
| Endeavor Resolute Rx Coronary Stent System | Coronary drug-eluting stent | 184 | 0 | 2.5% |
| Aneurx Aaadvantage Stent Graft System - Hydro | System, endovascular graft, aortic aneurysm treatment | 181 | 0 | 12.2% |
| Endeavor Rx Drug-Eluting Coronary Stent System | Coronary drug-eluting stent | 147 | 0 | 24.7% |
| Endurant Abdominal Stent Graft System | System, endovascular graft, aortic aneurysm treatment | 120 | 0 | 12.9% |
| Talent Thoracic Stent Graft System | System, endovascular graft, aortic aneurysm treatment | 108 | 0 | 26.7% |
| Endeavor Rx | Coronary drug-eluting stent | 40 | 0 | 35.3% |
| Talent Abdominal Stent Graft System | System, endovascular graft, aortic aneurysm treatment | 39 | 0 | 13.2% |
| Aneurx Aaadvantage Stent Graft System | System, endovascular graft, aortic aneurysm treatment | 35 | 0 | 13.6% |
| Endeavor Sprint Rx | Coronary drug-eluting stent | 15 | 0 | 28.5% |
| Nc Sprinter Rx | Catheters, transluminal coronary angioplasty, percutaneous | 8 | 41 | 1.1% |
| Endurant Stent Graft System | System, endovascular graft, aortic aneurysm treatment | 7 | 0 | 15.4% |
| Endurant Bifurcated Stent Graft | System, endovascular graft, aortic aneurysm treatment | 5 | 13 | 13.8% |
| Aneurx Abdominal Stent Graft System | System, endovascular graft, aortic aneurysm treatment | 3 | 0 | 15.5% |
Brands with a page on this site, ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Device types
| Product code | Device type | Reports | Share |
|---|---|---|---|
| NIQ | Coronary drug-eluting stent | 2,233 | 58.2% |
| MIH | System, endovascular graft, aortic aneurysm treatment | 1,083 | 28.2% |
| MAF | Stent, coronary | 287 | 7.5% |
| LOX | Catheters, transluminal coronary angioplasty, percutaneous | 195 | 5.1% |
| DQY | Catheter, percutaneous | 22 | 0.6% |
| FGE | Stents, drains and dilators for the biliary ducts | 9 | 0.2% |
| NIO | Stent, iliac | 6 | 0.2% |
| DQX | Wire, guide, catheter | 1 | 0% |
| LGW | Stimulator, spinal-cord, totally implanted for pain relief | 1 | 0% |
Reports by month, five years
FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
Event type
Grey bar: all 26,136,888 MAUDE reports. Event type is the filer's classification and is not verified by FDA.
Questions about Medtronic Cardiovascular Galway reports
How many FDA device reports name Medtronic Cardiovascular Galway as manufacturer?
3,837 reports through August 2026, 0 of them in the latest 12 months.
Which of its brands appear most often?
Endeavor Sprint Rx Coronary Stent System (1,029), Endeavor Rx Coronary Stent System (437), Talent Abdominal Stent Graft System - Hydro (263), Endeavor Resolute Rx Coronary Stent System (184) and Aneurx Aaadvantage Stent Graft System - Hydro (181).
Which device types does it report on?
coronary drug-eluting stent (58.2%), system, endovascular graft, aortic aneurysm treatment (28.2%), stent, coronary (7.5%) and catheters, transluminal coronary angioplasty, percutaneous (5.1%).
Does a high count say something about the manufacturer?
Not by itself. Manufacturers must file a report for every event they become aware of, so report volume follows the number of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. Manufacturer names are pooled after company suffixes (Inc., LLC, GmbH and similar) are dropped; names that read as a person rather than an organisation are never published. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.